MIRNAS AND INDICATORS OF MINERAL METABOLISM IN THE POPULATION OF DIALYSIS PATIENTS


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

miRNAs are molecules that play a role in the post-transcriptional regulation of gene expression. They involved in almost all biological processes. However the role in the development of mineral-bone disorders in the population of dialysis patients is still poorly understood. There is no data on the comparison of miRNA and FGF-23 expression patterns, as well as the level of ionized calcium and inorganic phosphorus, as well as the effect of phosphate binders. Objective: to evaluate associations between the levels of miRNA-21, miRNA-126 and miRNA-210 in serum with indicators of bone and mineral metabolism in hemo- and peritoneal dialysis patients. Material and methods: The study included 55 patients, of which 33 received maintenance hemodialysis treatment (HD), and 22 - peritoneal dialysis (PD). The control group consisted of 28 healthy volunteers. In all patients, except for routine examination methods: determining the level of calcium, inorganic phosphorus, parathyroid hormone (PTH) level, the level of expression of microRNA-21, microRNA-126 and microRNA-210 was determined by real-time polymerase chain reaction. The serum level of FGF- 23 was determined by ELISA (enzyme-linked immunosorbent assay). Results. The concentration of serum levels of FGF-23 in HD patients exceeded that of those on PD. The increase in the concentration of FGF-23 in the blood serum in patients on maintenance HD correlated with the vintage of dialysis treatment (rs=0,587; p=0,002). The positive correlation was found between the serum concentrations of FGF-23 and inorganic phosphorus (rs =0,4; p=0,01). The positive correlation was found between the serum concentrations of microRNA-126 and phosphorus (rs=0,324; p=0,003). The direct relationship was found between the serum concentrations of microRNA-126 and the level of FGF-23 (rs=0,322; p=0,024). The serum level of FGF-23 positively correlated with the serum PTH level (rs= 0,5; p=0,01). The direct relationship was found between the serum concentrations of microRNA-126 and microRNA-210 and the serum FGF-23 concentration (rs=0,23; p=0,04, and rs=0,62; p=0,024, respectively). In the group of patients receiving sevelamer carbonate, lower levels of FGF-23 (12.4±5.9) were noted, in contrast to the group that did not receive this drug (23±7.3; p=0.003) and PTH (110±27 ng/mL, in the non-treated group 340±15; p=0.01). Patients receiving sevelamer carbonate have lower levels of miRNA-126 (p=0,002). Conclusions. MicroRNA expression indices also reflect the state of mineral metabolism in dialysis patients. The positive correlation has been established between the level of miRNA-126 and miRNA-210 expression and the level of inorganic phosphorus in dialysis patients. The level of FGF-23 directly correlated with the serum level of parathyroid hormone, as well as "dialysis vintage". The use of phosphate binders, in particular sevelamer carbonate, can positively affect the expression of miRNAs involved in the pathogenesis of cardiovascular events

全文:

受限制的访问

作者简介

Anastasiia Rind

I.P. Pavlov First St. Petersburg State Medical University

Email: anastasiia.rind@gmail.com
PhD student of the Department of Nephrology and Dialysis

Ashot Essaian

I.P. Pavlov First St. Petersburg State Medical University

Email: essaian.ashot@gmail.com
Prof., Head of the Department of Nephrology and Dialysis

Michael Zaraiski

I.P. Pavlov First St. Petersburg State Medical University

Email: mzaraiski@yandex.ru
Prof., Department of Clinical Laboratory Diagnostics

参考

  1. Abdellatif M. Differential Expression of MicroRNAs in Different Disease States. Circ. Res. 2015;110:638-50.
  2. Cipollone F, Felicioni L., Sarzani R., et al. A unique microRNA signature associated with plaque instability in humans. Stroke. 2018;42:2556-63.
  3. Ding X.-Q., Ge P.-Ch., Liu Zh.Interaction between microRNA expression and classical risk factors in the risk of coronary heart disease. Sci. Rep. 2015;5:14925.
  4. Gacon J., Badacz R., Stçpien E., et al. Diagnostic and prognostic micro-RNAs in ischaemic stroke due to carotid artery stenosis and in acute coronary syndrome: a four-year prospective study. Kardiol. Pol. 2018;76(2):362-69. doi: 10.5603/KP.a2017.0243.
  5. Szeto C.C., Wang G., Ng J.K.C., et al. Urinary miRNA profile for the diagnosis of IgA nephropathy. BMC. Nephrol. 2019;20:77. https://doi.org/10.1186/s12882-019-1267-4
  6. Liu Z, Wang S., Mi Q.S., Dong Z. MicroRNAs in pathogenesis of acute kidney injury. Nephron. 2016;134:149-53. doi: 10.1159/000446551.
  7. Meuth V.M.-L., Burtey S., Maitrias P., et al. microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 2017;1863(Issue 1):337-45.
  8. Hamdorf M., Kawakita S., Everly M. The Potential of MicroRNAs as Novel Biomarkers for Transplant Rejection. J. Immunol. Res. 2017;2017:4072364. doi: 10.1155/2017/4072364.
  9. Chao C.T., Yuan T.H., Yeh H.Y., et al. Risk Factors Associated With Altered Circulating Micro RNA-125b and Their Influences on Uremic Vascular Calcification Among Patients With End-Stage Renal Disease. J. Am. Heart Assoc. 2019;8(2):e010805. doi: 10.1161/JAHA.118.010805. [PMID: 30646802; PMCID: PMC6497364].
  10. Oliveira R.B., Cancela A.L.E., Graciolli F.G., et al. Early Control of PTHand FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy? Clin. J. Am. Soc. Nephrol. 2010;5(2):286-91. Doi: 10.2215/ CJN.05420709.
  11. Khan Z., Suthanthiran M, Muthukumar T. MicroRNAs and Transplantation. Clin. Lab. Med. 2019;39(1):125-43. doi: 10.1016/j.cll.2018.10.003.
  12. Yavropoulou M.P, Vaios V., Makras P., et al. Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder. Biomed. 2020;8(12):601. doi: 10.3390/biomedicines8120601.
  13. Meuth V.M.-., Burtey S., Maitrias P., et al. microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 2018;1877(2):320-25.
  14. Peter W.L.St, Wazny L.D., Weinhandl E.D. Phosphate-binder use in US dialysis patients: Prevalence, costs, evidence, and policies. Am. J. Kidney Dis. 2020;71(2):246-53.
  15. Phan O., Maillard M., Malluche H.H., et al. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure. Biomed. Res.Int. 2015;2015:515606.
  16. Chen Q., Chen S., Zhao J., et al. MicroRNA-126: A new and promising player in lung cancer. Oncol. Lett. 2021;21(1):35. doi: 10.3892/ol.2020.12296.
  17. Celic T., Meuth V.M.-L., et al. SP288 Sevelamer treatment modulates microrna's expression in aorta of mice with chronic kidney disease. Nephrol. Dial. Transpl. 2015;30(Suppl. 3):475.
  18. Rosa de Alarcon, Begona Alburquerque-Gonzalez, Africa Fernandez-Valera, et al. Pharmacogenetic role of vitamin D-binding protein and vitamin D receptor polymorphisms in the treatment response of dialysis patients with secondary hyperparathyroidism, Nephrol. Dial. Transplant. 2021;gfab353.
  19. Neradova A., Wasilewski G., Prisco S., et al.Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failure, Nephrol. Dial. Transpl. 2021;gfab314.
  20. Torres P.U., Troya M.I., Dauverge M., et al. Independent effects of parathyroid hormone and phosphate levels on hard outcomes in non-dialysis patients: food for thought, Nephrol. Dial. Transpl. 2021;gfab308. https://doi.org/10.1093/ndt/gfab308
  21. Ginsberg C., Zelnick L.R., Block G.A., et al. Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease, Nephrol. Dial. Transpl. 2020;35(4):616-23. https://doi.org/10.1093/ndt/gfaa010
  22. Lee C.T., Lee Y.T., Tain Y.L., et al. Circulating microRNAs and vascular calcification in hemodialysis patients. J.Int. Med. Res. 2019;47(7):2929-39. doi: 10.1177/0300060519848949.

补充文件

附件文件
动作
1. JATS XML
##common.cookie##